Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical-pathological outcomes in non-small cell lung cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jiawei,Chen

第一单位： Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

作者： Jiawei,Chen ^[1] ; Hongsheng,Deng ^[1] ; Jiaxi,He ^[1] ; Zhufeng,Wang ^[2] ; Shuben,Li ^[1]

作者单位： Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ^[1] National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. ^[2]

关键词 neoadjuvant immunotherapy pathological outcomes surgery surgical safety time-to-surgery (TTS) interval

DOI 10.3389/fonc.2022.909726

PMID 36158657

发布时间 2022-09-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2022年12卷

909726页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical-pathological outcomes in non-small cell lung cancer.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical-pathological outcomes in non-small cell lung cancer.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除